NCT00414622View on ClinicalTrials.gov

GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

April 30, 2007

Conditions

Alzheimer Disease

Interventions

DRUG

DMXB-A

Trial Locations (1)

Unknown

Clinical Dept., 280 South San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CoMentis

INDUSTRY